

International Standard (ISRM) – Changes from November 2019 to June 2020

1. Definition *Administration*:

Administration: Providing, supplying, supervising, facilitating, or otherwise participating in the *Use* or *Attempted Use* by another *Person* of a *Prohibited Substance* or *Prohibited Method*. However, this definition shall not include the actions of bona fide medical personnel involving a *Prohibited Substance* or *Prohibited Method* ~~used~~Used for genuine and legal therapeutic purposes or other acceptable justification and shall not include actions involving *Prohibited Substances* which are not prohibited in *Out-of-Competition Testing* unless the circumstances as a whole demonstrate that such *Prohibited Substances* are not intended for genuine and legal therapeutic purposes or are intended to enhance sport performance.

2. Definition *National Anti-Doping Organization*:

National Anti-Doping Organization: The entity(ies) designated by each country as possessing the primary authority and responsibility to adopt and implement anti-doping rules, direct the collection of *Samples*, ~~the management of~~manage test results, and ~~the conduct of~~hearings Results Management at the national level. If this designation has not been made by the competent public authority(ies), the entity shall be the country's *National Olympic Committee* or its designee.

3. Definition *Prohibited List*:

Prohibited List: The ~~List~~list identifying the *Prohibited Substances* and *Prohibited Methods*.

4. Definition *Doping Control*:

Doping Control: All steps and processes from test distribution planning through to ultimate disposition of any appeal and the enforcement of *Consequences*, including all steps and processes in between, including but not limited to, *Testing*, investigations, whereabouts, *TUEs*, *Sample* collection and handling, laboratory analysis, *Results Management*, ~~hearings and appeals~~, and investigations or proceedings relating to violations of Article 10.14 (Status During *Ineligibility* or *Provisional Suspension*).

5. Article 3.7.6:

The “International Standard for *Results Management*” was abbreviated to “International Standard”.

3.7.6 The Annexes to the *International Standard for Results Management* have the same mandatory status as the rest of the *International Standard* ~~for Results Management~~.

6. Comment to Article 5.1.1.1:

TD DL was defined.

5.1.1.1 *Therapeutic Use Exemption*

5.1.1.1.1 The *Results Management Authority* shall consult the *Athlete’s* records in ADAMS and with other *Anti-Doping Organizations* that might have approved a *TUE* for the *Athlete* (e.g., the *National Anti-Doping Organization* or the *International Federation*) to determine whether a *TUE* exists.

*[Comment to Article 5.1.1.1.1: As per the Prohibited List and the ~~TD—DL~~ Technical Document for Decision Limits for the Confirmatory Quantification of Threshold Substances, the detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of certain Threshold Substances (identified in the Prohibited List), in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding unless the Athlete has an approved TUE for that substance in addition to the one granted for the diuretic or masking agent. Therefore, in the ~~Event~~event of such detection, the *Results Management Authority* shall also determine whether*

7. Article 5.1.2.2.b:

The following sentence was added:

- b) Urinary human chorionic gonadotrophin: follow the procedures set out at Article 6 of the 2019 Technical Document for the Reporting & Management of Urinary Human Chorionic Gonadotrophin (hCG) and Luteinizing Hormone (LH) Findings in Male Athletes (TD2019CG/LH) or any subsequent version of the *Technical Document*;

8. Comment to Article 6.4.1:

The following was added:

6.4 Notification

6.4.1 Unless already notified under another provision of this *International Standard*, any imposition of a *Provisional Suspension* notified to the *Athlete* or other *Person* or voluntary acceptance of a *Provisional Suspension*, or lifting of either, shall promptly be notified by the Results Management Authority to the *Athlete's* or other *Person's* *National Anti-Doping Organization(s)*, International Federation and WADA and shall promptly be reported into ADAMS.

[Comment to Article 6.4.1: To the extent not already set out in the communication to the Athlete or other Person, this notification shall include the following information (if applicable): the Athlete's or other Person's name, country, sport and discipline within the sport.]

9. Comment to Article 9.1.1.d

Specified Substances or Specified Methods was added. Changed “Contaminated Substances” to “Contaminated Products”:

d) Applicable *Consequences*; and

[Comment to Article 9.1.1 d): The decision shall identify the specific provisions on which the sanction, including any reduction or suspension, is based and provide reasons justifying the imposition of the relevant Consequences. In particular, where the applicable rules grant discretion to the hearing panel (e.g. for Specified Substances or Specified Methods or Contaminated SubstancesProducts under Code Article 10.6.1.1 and 10.6.1.2), the decision shall explain why the period of Ineligibility imposed is appropriate. The decision shall also indicate the start date of the period of Ineligibility (if any) and provide justifications in the event that this date is earlier than the date of the decision (see Code Article 10.13.1). The decision shall also indicate the period of Disqualification, with justification in the event that certain results are not Disqualified for reasons of fairness (Code Article 10.10 of the Code), and any forfeiture of medals or prizes. The decision shall also set if (and to what extent) any period of Provisional Suspension is credited against any period of Ineligibility ultimately imposed, and set out any other relevant Consequences based on the applicable rules, including Financial Consequences. As per Code Article 7.5.1, Major Event Organizations shall, however, not be required to determine Ineligibility or Financial Consequences beyond the scope of their Event.]

10. Article C.2.2.4.2

The term “consequences” was capitalized and italicized into “*Consequences*” to reflect the Code defined term of “*Consequences*”.

C.2.2.4.2 An Expert review initiated in the above-mentioned situations may result in the same ~~consequences~~*Consequences* as an Expert review triggered by an *Atypical Passport Finding*.

11. Article C.7.2

ESA is defined:

C.7.2 When an *Athlete* is found to have committed an anti-doping rule violation on any basis other than the *Athlete Biological Passport*, the haematological and/or Steroidal Passport will remain in effect, except in those cases where the *Prohibited Substance* or *Prohibited Method* caused an alteration of the haematological or steroidal *Markers*, respectively (e.g. for AAF reported for anabolic androgenic steroids, which may affect the *Markers* of the steroid profile, or for the Use of ~~ESAs~~Erythropoiesis Stimulating Agents or blood transfusions, which would alter the haematological *Markers*). The Passport Custodian shall consult with their *Athlete Passport Management Unit* following an *Adverse Analytical Finding* to determine whether a Passport reset is warranted. In such instances, the *Athlete*'s profile(s) would be reset from the time of the beginning of the sanction.